FDA approves first drug to improve symptoms in children with rare inherited heart condition
BMY•The FDA approved Camzyos (mavacamten) capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy. The drug carries a boxed warning for heart failure risk and is restricted to a REMS program.
1. FDA approval
The FDA approved Camzyos (mavacamten) capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms. The drug carries a boxed warning for heart failure risk and is restricted to a REMS program.
